ABSTRACT: Targeted α therapy holds tremendous potential as a cancer treatment: it offers the possibility of delivering a highly cytotoxic dose to targeted cells while minimizing damage to surrounding healthy tissue. The metallic α-generating radioisotopes 225 Ac and 227 Th are promising radionuclides for therapeutic use, provided adequate chelation and targeting. Here we demonstrate a new chelating platform composed of a multidentate high-affinity oxygen-donating ligand 3,4,3-LI(CAM) bound to the mammalian protein siderocalin. Respective stability constants log β 110 = 29.65 ± 0.65, 57.26 ± 0.20, and 47.71 ± 0.08, determined for the Eu III (a lanthanide surrogate for Ac III ), Zr IV , and Th IV complexes of 3,4,3-LI(CAM) through spectrophotometric titrations, reveal this ligand to be one of the most powerful chelators for both trivalent and tetravalent metal ions at physiological pH. The resulting metal−ligand complexes are also recognized with extremely high affinity by the siderophore-binding protein siderocalin, with dissociation constants below 40 nM and tight electrostatic interactions, as evidenced by X-ray structures of the protein:ligand:metal adducts with Zr IV and Th IV
■ INTRODUCTION
Targeted α therapy (TAT), or radioimmunotherapy that uses α-particle emitting nuclides, is a promising treatment strategy for small metastatic tumors and other localized diseases. Owing to α-particles' short path length, much of the decay energy may be deposited into target areas while mitigating damage to surrounding tissue. 1 A number of radionuclides that emit single α particles, including 211 At (t 1/2 = 7.2 h), 213 Bi (t 1/2 = 0.8 h), and 212 Bi (t 1/2 = 1.0 h), are currently under investigation. 2 A growing subset of the field includes in vivo α-generator radionuclides 225 Ac (t 1/2 = 10.0 d), 223 Ra (t 1/2 = 11.4 d), and 227 Th (t 1/2 = 18.7 d), isotopes that emit multiple α particles in their decay chains and dramatically increase the potential delivered dose. 3−6 This principle was recently exploited in the development of Alpharadin, 223 RaCl 2 , a drug for bone metastases. 7 While Alpharadin relies on the natural propensity of 223 Ra for bone, other specifically targeted α-radiation delivery strategies use constructs formed with chelating agents to complex metallic α-emitters and biological targeting vectors. 2 Though sound in theory, these designs have been slow to appear in the clinic, with only scarce examples of promising α-generator immunoconjugates, such as the lintuzumab conjugate 225 Ac-HuM195 8 and the sialic-acid receptor CD33 conjugate 227 Th-CD33-TTC 9 for myeloid leukemia treatment, or 227 Th-DOTA-trastuzumab for treating HER-2 positive breast and ovarian cancer. 10 Reasons for this slow development are largely economical and related to costs associated with radionuclide production, clinical material production, as well as preclinical and clinical studies. Nevertheless, a better understanding of radiometal chelation and biodistribution is also direly needed to advance this field and to provide new chelating platforms that may be tailored on the basis of indication and isotope selection.
The 225 Ac and 227 Th radioisotopes are members of the actinide (An) series of elements. They display high coordination numbers and are best chelated by high-denticity ligands that contain hard donor atoms, such as the multidentate hydroxypyridinone-based (HOPO) compounds, our workhorse ligands for in vivo actinide decorporation. 11 The ligand 3,4,3-LI(1,2-HOPO) is an octadentate, tetraprotic compound composed of 4 bidentate 1,2-HOPO metal-binding units attached onto a spermine ("3,4,3-LI") scaffold (Figure 1) . 3,4,3-LI(1,2-HOPO) was recently modified to enable monoclonal antibody attachment and form a bioconjugate chelator that displayed high in vivo stability when bound to 89 Zr, as imaged by positron emission tomography (PET). 12, 13 Similarly, an octadentate Me-3,2-HOPO bioconjugate chelator built on a slightly different symmetrical polyamine scaffold was recently prepared for the complexation of 227 Th, and it displayed fast radiolabeling kinetics.
14 Although successful, such modifications necessitate extensive synthetic procedures with low overall yields, 12, 14 which prompted us to investigate alternate routes to link therapeutic and imaging radionuclides to targeting moieties.
The mammalian 24 kDa glycoprotein siderocalin (Scn) is a member of the lipocalin protein superfamily. Scn is known to complement the innate immune system by binding specific bacterial siderophores and their ferric complexes, a mechanism that counters the iron acquisition pathway of invading microorganisms. 19 Our recent work revealed that Scn binds lanthanide (Ln) and An ions precomplexed with a suitable ligand in solution with very high affinity, through strong electrostatic interactions. 15 Although [Fe III (Ent)] 3− , the ferric complex of the hexadentate catecholate siderophore enterobactin (Ent) is Scn's native ligand, 16 the protein's sterically hindered binding pocket was shown to bind Ln and An complexes of Ent (Figure 1) . 15 More surprisingly, the protein also accommodates the much stronger Ln and An complexes formed with the octadentate synthetic analogue 3,4,3-LI(1,2-HOPO). 15 Building on this work, one can envision using the Scn−ligand−metal system as a radionuclide binder for TAT as well as a reporter ligand for concurrent diagnostics. The advantage of using a protein-mediated binding system is 2-fold: potentially tighter binding to nuclides of interest and easier attachment to targeting moieties by eliminating the need for post protein expression bioconjugate chemistry. The aforementioned  225 Ac  III and  227 Th  IV show promise in radioimmunotheraphy, while 89 Zr IV is useful as a PET tracer; all of these metals may be captured by the Scn−ligand system with some optimization. Upon single deprotonation of each of the 1,2-HOPO units (Figure 1 ), the overall negative 3,4,3-LI(1,2-HOPO) complexes of Ln III and An III are tightly bound by Scn, but the formally neutral 3,4,3-LI(1,2-HOPO) complexes of 4+ metals interact weakly. 15 The difference in binding originates from insufficient electrostatic interaction between the metal− ligand complex and Scn. In order to restore complex binding by Scn, we must use a ligand of high denticity that captures both 3+ and 4+ metals, forms overall negatively charged complexes, and does not cause steric clashes in Scn's tight binding pocket. This work aims to address the inability of the Scn-3,4,3-LI(1,2-HOPO) system to bind 4+ ions by exploring more suitable ligands that can complex both 3+ and 4+ metal ions. SO 4 , to prevent hydrolysis. The metal salt ZrCl 4 was handled and stored in a glovebox kept under inert atmosphere. The Zr IV stock solution was standardized against EDTA, with xylene orange as the indicator. 18 A Th IV stock solution was prepared in 0.1 M H 2 SO 4 . Stock solutions (4 mM) of Ent and 3,4,3-LI(CAM) were prepared by direct dissolution of a weighed portion of ligand in DMSO, and aliquots were removed prior to each set of experiments. Recombinant human Scn was prepared as previously described. 19 Incremental Spectrophotometric Titrations. This method was used to determine the protonation constants of 3,4,3-LI(CAM) as well as the stability constants of its complexes formed with Eu III , Zr IV , and 232 Th IV . The experimental titration setup is similar to previously described systems, and details are provided as Supporting Information. Protein-Binding Assay and Crystallography. Scn binding of metal−ligand complexes was measured by fluorescence quenching, as described previously 15, 21 and detailed in the Supporting Information. Diffraction-quality crystals were grown by vapor diffusion from drops containing the ternary metal− chelator−protein complex according to standard methods (Supporting Information). Diffraction data were collected on beamline 5.0.2 at the Advanced Light Source (ALS, Berkeley, CA) and processed as detailed in Supporting Information. Crystallographic statistics are reported in Supporting Information Table S1 . Final models have been deposited in the PDB. 22 In Vivo Biodistribution Assay. All procedures and protocols used in the presented in vivo studies were reviewed and approved by the Institutional Animal Care and Use Committee at Lawrence Berkeley National Laboratory and performed in AAALAC accredited facilities. The animals used were adult female CD-1 mice (180 ± 7 days old, 40. . Protein solutions were washed thrice with PBS using 10 kDa molecular weight cutoff membrane-based centrifugal filters, and all solutions were filtersterilized (0.22 μm) prior to injection. Under isoflurane anesthesia, groups of three normally fed mice were injected intravenously with 0.2 mL of a complex solution (370 Bq per mouse). After injection of the 238 Pu tracer, mice were weighed, identified, and housed in groups of three in plastic stock cages lined with a 0.5 cm layer of highly absorbent low-ash pelleted cellulose bedding (Alpha-dri) for separation of urine and feces. Mice were given water and food ad libitum and euthanized at 4, 24, or 48 h after tracer injection. All experiments using 238 Pu tracers were managed as metabolic balance studies, in which tissues and excreta were analyzed for 238 Pu by liquid scintillation counting on a Perkin-Elmer Packard Tri-Carb model B4430. The methods of sample collection, preparation, radioactivity measurements, and data reduction have been published previously. 23−25 Those methods provide quantitative measurements of radioactivity in biological samples; material recoveries averaged about 99% of the amount injected in these experiments.
■ METHODS

Caution
■ RESULTS AND DISCUSSION
Synthesis of Octadentate Ligand 3,4,3-LI(CAM).
Since electrostatic interactions between Scn and Ln/An complexes play a key role in binding, we chose to explore ligands that would form overall negative complexes with both 3+ and 4+ metals. Although Scn exhibits a broad, degenerate recognition mechanism for native siderophores, previous studies probing the extent of Scn binding to synthetic siderophore analogues showed that the Scn binding site allows only limited changes to its ligands. 21, 26 Thus, the simplest way to correct the binding would be to employ ligands with similar structural features. We chose to follow Occam's razor by using 3,4,3-LI(CAM) ( Figure  1 ), a compound first prepared by Raymond and co-workers for plutonium decorporation purposes. 27 This octadentate ligand leverages grafting of catecholamide (CAM) moieties found in microbial siderophores on the spermine scaffold to form a hybrid version of Ent and 3,4,3-LI(1,2-HOPO) that should (i) display increased complex stability over Ent due to its higher denticity and (ii) bear more negative charges than 3,4,3-LI(1,2-HOPO) due to CAM units requiring further deprotonation for metal binding (Figure 1) . 3,4,3-LI(CAM) was synthesized here from readily available building blocks using a process developed in-house (Scheme 1). The new preparation moves away from using harsh reaction conditions by using the protected diphenylmethylene acetal derivative (5), which greatly simplifies purification of the final product.
Affinity of 3,4,3-LI(CAM) toward 3+ and 4+ Metals. A comprehensive solution thermodynamic analysis was performed to characterize the affinity of 3,4,3-LI(CAM) for trivalent and tetravalent metals and to understand the effect of substituting 1,2-HOPO for CAM binding units on the octadentate spermine scaffold. The protonation constants of 3,4,3-LI(CAM) were determined by spectrophotometric titrations, and eight protonation equilibria were assigned to sequential removal of two protons from each of the four CAM units (Table 1) . Previous studies of Ent and other CAMcontaining synthetic analogues established that the protonation constants (pK a1 −pK a4 ) of the meta-hydroxyl oxygen atoms are well-separated from the ortho-hydroxyl oxygen atoms (pK a5 − pK a8 ). 28 The last four pK a values are most relevant to metal binding as moieties corresponding to these values have to be deprotonated at physiological pH in order to bind the metal ions. The overall acidity of 3,4,3-LI(CAM) can be defined as ∑pK a5−8 = 27.8 versus 3,4,3-LI (1,2-HOPO parts, with log β 110 values of 29.7, 47.7, and 57.3, respectively. Consequently, 3,4,3-LI(CAM) is one of the strongest ligands ever reported for the chelation of both trivalent and tetravalent f-elements. For comparison, a cyclic octadentate terephthalamide derivative was recently designed to bind Th 4+ in vivo and showed an unprecedented affinity for Th 4+ with a log β 110 (ThL 4− ) value of 53.7. 30 It is worth mentioning, however, that terephthalamide ligands would not be recognized by Scn, due to steric hindrance generated by the bulky substituents on the para position of the catecholate-like unit. To inspect the pH dependency of metal complex formation, speciation diagrams were calculated for 3,4,3-LI(CAM) in the presence of 1 equivalent of Eu , being predominant at physiological pH (7.4) . This behavior departs from that of 3,4,3-LI(1,2-HOPO), with which 4 + metal complexes are formed even under very acidic conditions (pH < 0). 31 (Figure 2 ). As hypothesized, these data demonstrate a substantial difference in protein recognition between the 3,4,3-LI(CAM) and 3,4,3-LI(1,2-HOPO) complexes of tetravalent metals. Use of the diprotic CAM units in lieu of the monoprotic 1,2-HOPO moieties led to the formation of negatively charged complexes, enabling electrostatic interactions with the protein trilobal calyx. Moreover, while the addition of a fourth CAM metal-binding group in the octadentate 3,4,3-LI(CAM) was important for increased stability of the metal−ligand complexes at pH 7.4, it did not prevent the high Scn affinities initially observed with hexacoordinated Ent complexes. Subtle differences were observed with the recognition patterns: for similarly charged Zr IV , 7 and Th IV8 complex formation constants previously reported for 3,4,3-LI(1,2-HOPO) are also given for comparison. 15 and was confirmed here with Zr IV , while no significant differences are discernible with 3,4,3-LI (1,2-HOPO) .
Structural Characterization of Scn-3,4,3-LI(CAM) Adducts. X-ray crystallography was used as previously described 15 to determine the structures of the Scn adducts formed with the 232 Th-3,4,3-LI(CAM) and Zr-3,4,3-LI(CAM) complexes (Table S1 ). As expected, and as observed in previous Scn complex structures (e.g., with 243 Am-3,4,3-LI (1,2-HOPO) ), 15 the compounds are bound in the deeply recessed trilobal binding site, or calyx, of Scn (Figure 3a−c) . As in previous structures of Scn bound to CAM-bearing ligands with An ions, only one CAM substituent is ordered in the crystal structures along with the bound metal, Zr or Th. This was likely a result of the remainder of the chelator sampling multiple conformations between molecules in the crystal, but clearly confirmed binding of chelator and metal in both adducts. The CAM substituent bound in the key binding pocket in the Scn calyx, between the side-chains of two bracketing lysine residues (K125 and K134; Figure 3d ). The structure of the Scn calyx is highly conserved with prior structures, reflecting its rigidity, with the side-chains of two residues, W79 and R81, as the only elements flexing to accommodate different ligands (Figure 3e ). In prior Ent or Ent analogue chelator/actinide structures, 15 where two of the three CAM groups are also disordered, the side-chain of W79 adopted an unusual rotamer, flipping inward toward the metal to contribute a cation−π interaction. However, in these structures, this side-chain adopts more conventional orientations, either sampling multiple rotamers, rendering it disordered in the crystallographic analysis (in the Zr complex), or lying against the calyx wall in the Th complex. Apart from these two side-chains, the overall impression conveyed by these and previous results is that the chelator flexes and distorts to fit in an essentially rigid and unyielding calyx. 238 Pu was found in the urine than in the feces. However, the kidney and liver contents reveal a key difference in excretion pattern: when free, the 3,4,3-LI(CAM) complex is predominantly found in the liver at early time points after administration and follows a biliary pathway, similar to what is known for HOPO complexes. However, insertion within the protein favors elimination through the renal system, with up to ∼52% of 238 Pu found in the kidneys 4 h after administration of the Scn adducts, a burden that subsequently In this structure, the side-chain of W79 is disordered, indicated by the yellow dashed circle, due to sampling of multiple rotamers in the complex, allowing much more of the surface of R81 to be seen. Only one substituent CAM group and the actinide (aqua sphere) are ordered and visualized in the complex crystal structure, as had been seen in a previous hexadentate CAM/actinide/Scn structure. 15 The one ordered CAM moiety sits in the key binding pocket defined by the side-chains of K125 and K134. 225 Ac III ) metallic radioisotopes may be used in conjunction for dual diagnostics/treatment applications. Our results illustrate the promise of this system. It is also likely that, with further tuning, a more effective protein−ligand arrangement may be developed: current work is underway to explore other ligands based on the 3,4,3-LI scaffold in order to reconcile the metal/ protein binding compromise by incorporating both monoprotic HOPO and diprotic CAM units. Finally, future efforts will focus on evaluating the kinetics of release of different radionuclides from the Scn:ligand systems, as well as the distribution of daughter products. We will perform in vitro and in vivo studies with the more suited medical isotopes 225 Inorg. Chem. XXXX, XXX, XXX−XXX
